Genmab A/S
Genmab A/S (GMAB) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · GMAB · as of Jun 8, 2026
Key Statistics
Explore Genmab A/S Data
gmab stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 17 · Buy rate: 70.6%
The GMAB analyst consensus is Buy, based on ratings from 17 Wall Street analysts over the past 3 months. The average 12-month price target is $38.30, representing +52.29% upside from the current price of $25.15.
Competitors & Peers
gmab competitorsGMAB
DGX
EXEL
ILMN
INCY
ROIVStock Performance
Full HistoryAbout Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients w…
what is genmab a/s · gmab stock overview · genmab a/s company profile · who is genmab a/s ceo · gmab NASDAQ · genmab a/s headquarters · genmab a/s business segments
About Stock Overview & Key Data
Genmab A/S (GMAB) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jun 1, 2009. As of the latest trading session, GMAB stock price is $25.15, with a market capitalization of $15.4B. The stock has returned +13.03% over the past 12 months and -18.34% year-to-date.
According to 17 Wall Street analysts, the consensus rating for Genmab A/S stock is Buy, with an average 12-month price target of $38.30. In fiscal year 2025, Genmab A/S reported revenue of $3.7B and net income of $963.8M. For detailed data — including Genmab A/S revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Genmab A/S (GMAB) stock price is $25.15. The stock is traded on NASDAQ under the ticker symbol GMAB. The 52-week range is $20.23 – $35.43.